Abbvie Inc (ABBV)

$200.50 -4.62 (-2.25%)
Market Cap 362.69B
Revenue (ttm) 61.16B
Net Income (ttm) 4.23B
EPS (ttm) N/A
PE Ratio 20.37
Forward PE 14.29
Profit Margin 6.91%
Debt to Equity Ratio -20.91
Volume 7,646,200
Avg Vol 6,914,978
Day's Range N/A - N/A
Shares Out 1.77B
Stochastic %K 5%
Beta 0.38
Analysts Strong Sell
Price Target $250.10

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 847 932 7900
Address:
1 North Waukegan Road, North Chicago, United States
ClearStrategies
ClearStrategies Apr. 23 at 8:52 AM
$ABBV
0 · Reply
ModernFlow
ModernFlow Apr. 23 at 5:09 AM
$ABBV pharmaceutical company with strong cash flow and diversified drug revenue
0 · Reply
fxshea
fxshea Apr. 23 at 5:01 AM
$ABBV Drop maybe due to reclassification of marijuana?
1 · Reply
ModernFlow
ModernFlow Apr. 23 at 4:18 AM
$ABBV pharmaceutical company supported by diversified drug revenue and attractive shareholder returns
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Apr. 23 at 3:30 AM
$SLS $ABBV Positive P3 Registrational Results will give Gps the FDA Green Light to treat upwards of 50,000 AML Patients Each year +100,000 Currently in remission. xCCo estimated a Minimum of $280K Rev Per Patient $28B TAM Year 1 and Revenue Compounds, with infinite Dosing Regime. $RVMD added $15B in Market Value in a Day, Based on its Phase 3 Results ... Same thing will be happening Here. Could Be Any Day Now.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Apr. 23 at 12:29 AM
$SLS $ABBV Who's Getting Short Conned?? No REAL Holders Are Letting any Go before the P3 Results are announced - and Smart Money is accumulating Every Cheap Short Sold Share the Manipulators will sell.
1 · Reply
HydrogenH2
HydrogenH2 Apr. 22 at 9:41 PM
$ABBV adding more... Thanks to crazy bashers here .. I"m buying more... quality pharma... !! great dividend also.... !!
0 · Reply
Oldpuck
Oldpuck Apr. 22 at 9:32 PM
$ABBV Why is ABBV getting crushed
1 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Apr. 22 at 9:30 PM
$SLS $ABBV - How Long is Too Long for Institutional fund money to See a Potential 4,000% to 6,000% ROI ? We could see a Spate of Rapid Events, this far along - 62 months, in a Survival Based Phase 3 trial, with enrollment concluding a solid 25 months ago - in a AML CR2 Transplant Ineligible Setting, where Known MOS for control on BAT is ~ 8 months - Event Rates are Not Linear 62 - 25 month Range of OS - Very Possible several events occur in 1 months time - and the 80th would be announced. - Really could be Any Day Now. AND FOR SURE NOT MUCH LONGER - HOW Long is Too Long for Institutional fund money to See a Potential 4,000% ROI ???
0 · Reply
HydrogenH2
HydrogenH2 Apr. 22 at 9:15 PM
$ABBV
0 · Reply
Latest News on ABBV
AbbVie to build $1.4 billion manufacturing campus in North Carolina

Apr 22, 2026, 12:59 PM EDT - 17 hours ago

AbbVie to build $1.4 billion manufacturing campus in North Carolina

AbbVie Selects North Carolina for New $1.4 Billion Manufacturing Campus

Apr 22, 2026, 12:02 PM EDT - 18 hours ago

AbbVie Selects North Carolina for New $1.4 Billion Manufacturing Campus

Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases

Apr 20, 2026, 2:30 AM EDT - 3 days ago

Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields

Apr 15, 2026, 8:16 AM EDT - 7 days ago

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields

MDT

Erin Lichy Gets Real About Her Natrelle® Breast Augmentation

Apr 14, 2026, 8:50 AM EDT - 8 days ago

Erin Lichy Gets Real About Her Natrelle® Breast Augmentation

Haisco Enters into Exclusive License Agreement with AbbVie to Develop Novel Medicines for Pain

Apr 13, 2026, 2:24 AM EDT - 10 days ago

Haisco Enters into Exclusive License Agreement with AbbVie to Develop Novel Medicines for Pain

AbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026

Apr 12, 2026, 7:15 AM EDT - 10 days ago

AbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026

AbbVie files lawsuit to address 'outdated' drug discount eligibility program

Apr 8, 2026, 1:38 PM EDT - 14 days ago

AbbVie files lawsuit to address 'outdated' drug discount eligibility program

BOTOX® Cosmetic (onabotulinumtoxinA) Empowers Women Entrepreneurs Through "The Confidence Collective" for Fourth Year

Apr 8, 2026, 8:00 AM EDT - 14 days ago

BOTOX® Cosmetic (onabotulinumtoxinA) Empowers Women Entrepreneurs Through "The Confidence Collective" for Fourth Year

The price Americans pay for medicine has gotten horribly out of control. Here's how to fix it.

Apr 7, 2026, 9:53 AM EDT - 15 days ago

The price Americans pay for medicine has gotten horribly out of control. Here's how to fix it.

Allergan Aesthetics Third State-of-the-Art AMI Center Opens in Austin

Apr 7, 2026, 9:00 AM EDT - 15 days ago

Allergan Aesthetics Third State-of-the-Art AMI Center Opens in Austin

Swiss industry body says US tariffs on pharmaceuticals will harm patients

Apr 3, 2026, 11:08 AM EDT - 19 days ago

Swiss industry body says US tariffs on pharmaceuticals will harm patients

AMGN AZN BMY MRK NVO

Trump Administration Unveils Up to 100% Tariff on Branded Drugs

Apr 2, 2026, 5:34 PM EDT - 20 days ago

Trump Administration Unveils Up to 100% Tariff on Branded Drugs

AZN NVO AMGN BMY MRK

Trump threatens 100% tariff on US drug makers that don't strike deals to lower prices

Apr 2, 2026, 5:33 PM EDT - 20 days ago

Trump threatens 100% tariff on US drug makers that don't strike deals to lower prices

AMGN AZN BMY MRK NVO

Drugmakers face 100% tariff unless they cut prices or produce drugs in US

Apr 2, 2026, 3:29 PM EDT - 20 days ago

Drugmakers face 100% tariff unless they cut prices or produce drugs in US

AZN NVO AMGN BMY MRK

Global pharma companies that have publicly announced Trump drug pricing agreements

Apr 2, 2026, 2:59 PM EDT - 20 days ago

Global pharma companies that have publicly announced Trump drug pricing agreements

AMGN AZN BMY MRK

Allergan Aesthetics Announces Fourth Annual, All-Access CoolMonth with Deals on CoolSculpting®

Mar 31, 2026, 8:05 AM EDT - 22 days ago

Allergan Aesthetics Announces Fourth Annual, All-Access CoolMonth with Deals on CoolSculpting®

AbbVie to Host First-Quarter 2026 Earnings Conference Call

Mar 31, 2026, 8:00 AM EDT - 22 days ago

AbbVie to Host First-Quarter 2026 Earnings Conference Call

AbbVie to Highlight New Clinical and Real-World Evidence Advancing Standards of Care in Immune-Mediated Skin Diseases at the 2026 AAD Annual Meeting

Mar 27, 2026, 10:00 AM EDT - 26 days ago

AbbVie to Highlight New Clinical and Real-World Evidence Advancing Standards of Care in Immune-Mediated Skin Diseases at the 2026 AAD Annual Meeting

AbbVie Named Official Pharmaceutical Partner of Major League Baseball

Mar 24, 2026, 8:00 AM EDT - 4 weeks ago

AbbVie Named Official Pharmaceutical Partner of Major League Baseball

US FDA flags seizure risk with certain Parkinson's drugs, seeks label warnings

Mar 20, 2026, 12:11 PM EDT - 4 weeks ago

US FDA flags seizure risk with certain Parkinson's drugs, seeks label warnings

AMRX NVS OGN

Buy Or Fear AbbVie Stock At $210?

Mar 19, 2026, 9:26 AM EDT - 4 weeks ago

Buy Or Fear AbbVie Stock At $210?

Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions

Mar 19, 2026, 3:00 AM EDT - 5 weeks ago

Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions

TrumpRx lists many medicines at prices higher than paid in UK

Mar 18, 2026, 2:23 PM EDT - 5 weeks ago

TrumpRx lists many medicines at prices higher than paid in UK

AMGN AZN BMY GILD GSK JNJ LLY

Big drugmakers must face US overcharge claims on medications for low-income patients

Mar 17, 2026, 2:32 PM EDT - 5 weeks ago

Big drugmakers must face US overcharge claims on medications for low-income patients

AZN NVS SNY

New York Plastic Surgical Group and Deep Blue Med Spa Named #1 in New York by Allergan Aesthetics for the Second Year in a Row

Mar 13, 2026, 9:00 AM EDT - 5 weeks ago

New York Plastic Surgical Group and Deep Blue Med Spa Named #1 in New York by Allergan Aesthetics for the Second Year in a Row

AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults

Mar 9, 2026, 8:00 AM EDT - 6 weeks ago

AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults

AbbVie to Present at the Leerink Partners Global Healthcare Conference

Mar 3, 2026, 8:00 AM EST - 7 weeks ago

AbbVie to Present at the Leerink Partners Global Healthcare Conference

AbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI® (Risankizumab) Subcutaneous Induction in Patients with Crohn's Disease

Mar 2, 2026, 8:30 AM EST - 7 weeks ago

AbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI® (Risankizumab) Subcutaneous Induction in Patients with Crohn's Disease

AbbVie to Present at the TD Cowen 46th Annual Health Care Conference

Feb 24, 2026, 8:00 AM EST - 2 months ago

AbbVie to Present at the TD Cowen 46th Annual Health Care Conference

AbbVie to invest $380 million to expand US manufacturing in Illinois

Feb 23, 2026, 12:03 PM EST - 2 months ago

AbbVie to invest $380 million to expand US manufacturing in Illinois

AbbVie to Invest $380 Million in North Chicago to Further Expand Active Pharmaceutical Ingredient Manufacturing in the United States

Feb 23, 2026, 11:00 AM EST - 2 months ago

AbbVie to Invest $380 Million in North Chicago to Further Expand Active Pharmaceutical Ingredient Manufacturing in the United States

U.S. Food and Drug Administration (FDA) Approves Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL)

Feb 20, 2026, 2:00 AM EST - 2 months ago

U.S. Food and Drug Administration (FDA) Approves Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL)

AbbVie Declares Quarterly Dividend

Feb 19, 2026, 9:37 AM EST - 2 months ago

AbbVie Declares Quarterly Dividend

AbbVie sues US health agency over Botox price controls

Feb 11, 2026, 6:49 PM EST - 2 months ago

AbbVie sues US health agency over Botox price controls

Abbvie sues US health agency over Botox

Feb 11, 2026, 5:13 PM EST - 2 months ago

Abbvie sues US health agency over Botox

AbbVie's Inflammation Drug Humira Slows, But Skyrizi, Rinvoq Drive Revenue Growth

Feb 4, 2026, 12:38 PM EST - 2 months ago

AbbVie's Inflammation Drug Humira Slows, But Skyrizi, Rinvoq Drive Revenue Growth

AbbVie Revenue Rises on Immunology Growth

Feb 4, 2026, 8:34 AM EST - 2 months ago

AbbVie Revenue Rises on Immunology Growth

AbbVie Earnings Beat Wall Street Expectations. The Stock Is Falling Anyway.

Feb 4, 2026, 8:18 AM EST - 2 months ago

AbbVie Earnings Beat Wall Street Expectations. The Stock Is Falling Anyway.

AbbVie forecasts 2026 profit above estimates on strong sales of newer immunology drugs

Feb 4, 2026, 7:51 AM EST - 2 months ago

AbbVie forecasts 2026 profit above estimates on strong sales of newer immunology drugs

AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results

Feb 4, 2026, 7:48 AM EST - 2 months ago

AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results

Allergan Aesthetics Continues Its Mission of Empowering Women Through the Faces of Natrelle® Testimonial Program

Feb 3, 2026, 8:50 AM EST - 2 months ago

Allergan Aesthetics Continues Its Mission of Empowering Women Through the Faces of Natrelle® Testimonial Program

AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Adults and Adolescents With Vitiligo

Feb 3, 2026, 8:00 AM EST - 2 months ago

AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Adults and Adolescents With Vitiligo

AbbVie Launches Love in Mind™ to Spotlight the Emotional Impact of Migraine on Romantic Relationships

Jan 29, 2026, 8:00 AM EST - 2 months ago

AbbVie Launches Love in Mind™ to Spotlight the Emotional Impact of Migraine on Romantic Relationships

Allergan Aesthetics Unveils New Data Across Facial Injectables On-Market and Emerging Portfolio at IMCAS 2026 Showcasing Enduring Strength in Advancing Aesthetics Medicine

Jan 28, 2026, 8:00 AM EST - 3 months ago

Allergan Aesthetics Unveils New Data Across Facial Injectables On-Market and Emerging Portfolio at IMCAS 2026 Showcasing Enduring Strength in Advancing Aesthetics Medicine

US Medicare names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks

Jan 27, 2026, 4:52 PM EST - 3 months ago

US Medicare names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks

LLY PFE

The AbbVie Foundation Is Now Accepting Applications to Participate in the 2026 AbbVie Foundation Health Equity Accelerator

Jan 27, 2026, 9:34 AM EST - 3 months ago

The AbbVie Foundation Is Now Accepting Applications to Participate in the 2026 AbbVie Foundation Health Equity Accelerator

AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Jan 16, 2026, 1:43 PM EST - 3 months ago

AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Genmab and AbbVie's blood cancer drug fails to improve survival in late-stage study

Jan 16, 2026, 1:35 PM EST - 3 months ago

Genmab and AbbVie's blood cancer drug fails to improve survival in late-stage study

GMAB

AbbVie plans to build out its presence in obesity market

Jan 14, 2026, 2:01 PM EST - 3 months ago

AbbVie plans to build out its presence in obesity market

ClearStrategies
ClearStrategies Apr. 23 at 8:52 AM
$ABBV
0 · Reply
ModernFlow
ModernFlow Apr. 23 at 5:09 AM
$ABBV pharmaceutical company with strong cash flow and diversified drug revenue
0 · Reply
fxshea
fxshea Apr. 23 at 5:01 AM
$ABBV Drop maybe due to reclassification of marijuana?
1 · Reply
ModernFlow
ModernFlow Apr. 23 at 4:18 AM
$ABBV pharmaceutical company supported by diversified drug revenue and attractive shareholder returns
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Apr. 23 at 3:30 AM
$SLS $ABBV Positive P3 Registrational Results will give Gps the FDA Green Light to treat upwards of 50,000 AML Patients Each year +100,000 Currently in remission. xCCo estimated a Minimum of $280K Rev Per Patient $28B TAM Year 1 and Revenue Compounds, with infinite Dosing Regime. $RVMD added $15B in Market Value in a Day, Based on its Phase 3 Results ... Same thing will be happening Here. Could Be Any Day Now.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Apr. 23 at 12:29 AM
$SLS $ABBV Who's Getting Short Conned?? No REAL Holders Are Letting any Go before the P3 Results are announced - and Smart Money is accumulating Every Cheap Short Sold Share the Manipulators will sell.
1 · Reply
HydrogenH2
HydrogenH2 Apr. 22 at 9:41 PM
$ABBV adding more... Thanks to crazy bashers here .. I"m buying more... quality pharma... !! great dividend also.... !!
0 · Reply
Oldpuck
Oldpuck Apr. 22 at 9:32 PM
$ABBV Why is ABBV getting crushed
1 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Apr. 22 at 9:30 PM
$SLS $ABBV - How Long is Too Long for Institutional fund money to See a Potential 4,000% to 6,000% ROI ? We could see a Spate of Rapid Events, this far along - 62 months, in a Survival Based Phase 3 trial, with enrollment concluding a solid 25 months ago - in a AML CR2 Transplant Ineligible Setting, where Known MOS for control on BAT is ~ 8 months - Event Rates are Not Linear 62 - 25 month Range of OS - Very Possible several events occur in 1 months time - and the 80th would be announced. - Really could be Any Day Now. AND FOR SURE NOT MUCH LONGER - HOW Long is Too Long for Institutional fund money to See a Potential 4,000% ROI ???
0 · Reply
HydrogenH2
HydrogenH2 Apr. 22 at 9:15 PM
$ABBV
0 · Reply
prismmarketview
prismmarketview Apr. 22 at 8:44 PM
#AbbVie is investing $1.4B in a new manufacturing campus in Durham, NC. 700+ jobs, long‑term capacity for core franchises. Not just talk—real bricks & mortar. $ABBV https://prismmarketview.com/abbvie-bets-big-on-durham-1-4-billion-campus-to-power-its-next-generation-of-medicines/
0 · Reply
iQuicky
iQuicky Apr. 22 at 8:39 PM
$ABBV this is the bottom or near of it
0 · Reply
jbops3
jbops3 Apr. 22 at 8:12 PM
$ABBV my children you did well and im proud of you. we didnt quite meet our goals today but thats ok. we are aiming for sub $180 up to earnings and im confident that we will get there. this one is notorious for tanking after great earnings, imagine if the earnings are bad. so dump all tomorrow before more wreckage next week. you dont deserve anymore losses. you have to stop letting yourself become the victim.
0 · Reply
crtlabz
crtlabz Apr. 22 at 7:54 PM
$ABBV starting to take some serious legs down. Lately, $12-$15K clips down each day, but been here since $36 - just bitching a little. New money will flow in the $190's.
0 · Reply
Donib11
Donib11 Apr. 22 at 7:36 PM
$ABBV everyone is bearish so I’m buying calls
0 · Reply
jbops3
jbops3 Apr. 22 at 7:12 PM
$ABBV im the messiah of this board. as you can see, no one dares to counter my points because i only speak the truth. dump this shit now before it's too late. be free. dont be stubborn. this is going sub 200.
1 · Reply
jbops3
jbops3 Apr. 22 at 6:52 PM
$ABBV guys just one more hour to save your hard earned cash. Your life sucks already, you dont deserve to lose even more. Cut your losses and be free of this junk stock. You will win again with other stocks trust me. Get the hell out of this now and make me proud.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Apr. 22 at 6:49 PM
$SLS $PFE $LLY $ABBV Smarter than you, know this Enhanced Dosing Discovery by Harvard Professor, Dr. Amrein Completely deRisks 009. Dr. Amrein's data Confirms 009 Future Data - will Be Better - than Prior P2B SLS009 data published at ASH, - which was better than data that got bought for $4.9B. $SLS $0.888B 600% ROI on the Table - FREE MONEY
0 · Reply
jbops3
jbops3 Apr. 22 at 6:42 PM
$ABBV hell yes bittches lets go keep dumping. selling now will be the smarter choice at this point. this is going sub 200 why wait and lose even more money?? the forecast is 14 pe dude. will abbv earning skyrocket or will its stock price tank to meet that 14 pe??? think about it
0 · Reply
jbops3
jbops3 Apr. 22 at 6:33 PM
$ABBV trailing pe 88. forward pe 14. is abbvie suddenly gonna make 6x their previous earnings? does any company make 6x their previous earnings? miso hawney💦💦
0 · Reply
focafoca99
focafoca99 Apr. 22 at 6:30 PM
$ABBV selected North Carolina for a new $1.4 billion manufacturing campus. https://www.rapidticker.com/news/abbv-abbvie-selects-north-carolina-for-994874
0 · Reply
V9RDPUMA
V9RDPUMA Apr. 22 at 6:06 PM
$ABBV Why is this grinding lower? No negative news I can find.
1 · Reply